Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.82 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.79 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.79 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | LTA4H | P09960 | 3/20 | 0.66 |
| ▸ | MAOB | P27338 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694433 | 0.98 | KDM4E (0.97) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL12780029 | 0.98 | KDM4E (0.97) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL17300729 | 0.97 | KDM4E (0.94) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL10212085 | 0.92 | HRH3 (0.97) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL10212086 | 0.90 | HRH3 (1.00) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL19716249 | 0.90 | PSMB1 (0.97) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL678629 | 0.89 | KDM4E (0.79) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL17300724 | 0.89 | HRH3 (0.91) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL7490529 | 0.88 | HRH3 (1.00) | KDM4EHRH3MAOB | |
| SCHEMBL25531140 | 0.86 | KDM4E (0.74) | KDM4EHRH3PSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20200299276-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080176847-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885HRH3 1487/4885PSMB1 4593/4885 |
| US-11524955-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | IRAK4, IRAK1, IRAK3 | KDM4E 817/4885HRH3 132/4885PSMB1 1515/4885 |
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | KDM4E 1695/4885HRH3 4083/4885PSMB1 4494/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885HRH3 1487/4885PSMB1 4593/4885 |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | KDM4E 4036/4885HRH3 1145/4885PSMB1 2796/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | KDM4E 1689/4885HRH3 1487/4885PSMB1 4593/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KDM4E 4157/4885HRH3 3296/4885PSMB1 4526/4885 |
| US-20080176847-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, ERBB2, TYRO3 | KDM4E 3533/4885HRH3 846/4885PSMB1 2778/4885 |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | CDK6, ESR1, CDK4 | KDM4E 543/4885HRH3 2518/4885PSMB1 1043/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | KDM4E 1724/4885HRH3 4216/4885PSMB1 4587/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KDM4E 4157/4885HRH3 3296/4885PSMB1 4526/4885 |
| US-10710983-B2 | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | IRAK4, IRAK1, IRAK2 | KDM4E 516/4885HRH3 176/4885PSMB1 1739/4885 |
| US-20200299276-A1 | 2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK4, IRAK1, IRAK3 | KDM4E 788/4885HRH3 147/4885PSMB1 1463/4885 |
| US-20080188454-A1 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | AXL, FLT3, FLT1 | KDM4E 1218/4885HRH3 2092/4885PSMB1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.